Q1 Earnings Forecast for Biohaven Issued By Leerink Partnrs

Biohaven Ltd. (NYSE:BHVN - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Biohaven in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per share of ($1.79) for the quarter. The consensus estimate for Biohaven's current full-year earnings is ($8.90) per share. Leerink Partnrs also issued estimates for Biohaven's Q2 2025 earnings at ($1.82) EPS, Q3 2025 earnings at ($1.84) EPS and Q4 2025 earnings at ($1.55) EPS.

A number of other equities analysts have also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on shares of Biohaven and gave the stock a "buy" rating in a research report on Thursday, March 20th. Royal Bank of Canada reissued an "outperform" rating and set a $61.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. JPMorgan Chase & Co. cut their price target on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Morgan Stanley lowered their price objective on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Finally, HC Wainwright restated a "buy" rating and issued a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $62.77.

Biohaven Trading Up 9.2 %

NYSE BHVN traded up $1.73 during trading hours on Wednesday, reaching $20.41. The company had a trading volume of 2,098,008 shares, compared to its average volume of 1,110,098. The stock has a market capitalization of $2.08 billion, a P/E ratio of -2.18 and a beta of 1.33. The stock has a 50-day moving average of $28.43 and a 200 day moving average of $38.58. Biohaven has a 1-year low of $15.79 and a 1-year high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29).

Insider Buying and Selling at Biohaven

In related news, Director John W. Childs bought 32,700 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This represents a 1.43 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 16.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Biohaven

A number of hedge funds have recently bought and sold shares of BHVN. HighTower Advisors LLC bought a new position in Biohaven during the 3rd quarter worth approximately $276,000. Barclays PLC increased its holdings in shares of Biohaven by 87.6% in the 3rd quarter. Barclays PLC now owns 268,077 shares of the company's stock worth $13,396,000 after acquiring an additional 125,189 shares during the period. Geode Capital Management LLC increased its stake in shares of Biohaven by 2.6% in the third quarter. Geode Capital Management LLC now owns 1,714,612 shares of the company's stock valued at $85,696,000 after purchasing an additional 44,174 shares during the period. Sanctuary Advisors LLC bought a new stake in Biohaven during the 3rd quarter valued at $246,000. Finally, Franklin Resources Inc. raised its stake in shares of Biohaven by 0.5% during the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company's stock valued at $4,206,000 after purchasing an additional 412 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.